gip

GIP (1-30) amide (Human) is an insulin-dependent glucose-dependent polypeptide.The sugar-dependent insulin polypeptide (GIP) is an insulin secreting hormone, which can stimulate the secretion of insulin and reduce the occurrence of postpranal-glycemic dis

Endogenous truncated form of the incretin hormone GIP. More potent at stimulating glucose-dependent insulin secretion from rat pancreatic β-cells than GIP.

GIP (human) acetate is a stimulator of glucose-dependent insulin secretion and a weak inhibitor of gastric acid secretion. GIP (human) acetate plays a vital role in lipid metabolism and the development of obesity.

GIP (3-42), human (Gastric Inhibitory Polypeptide (3-42) (human)) is a peptide that acts as a glucose-dependent proinsulinotropic polypeptide (GIP) receptor antagonist and regulates insulin secretion and the metabolic effects of GIP in vivo, which can be used to study type 2 diabetes.

GIP (1-30) amide, porcine acetate is an agonist of fully glucose-dependent insulinotropic polypeptide (GIP) receptor. GIP (1-30) amide, porcine acetate can weakly inhibit gastric acid secretion and strongly stimulate insulin.

GIP (3-42), human acetate is an antagonist of a glucose-dependent insulinotropic polypeptide (GIP) receptor and regulates insulin secretion and GIP metabolism in vivo.

GIP (1-30) amide, porcine TFA is a high-affinity full agonist of the glucose-dependent insulinotropic polypeptide (GIP) receptor, with potency comparable to native GIP(1-42) [1]. It also exhibits potent insulin-stimulating properties and weakly inhibits gastric acid secretion.

GIP (1-30) amide (Human) TFA is a glucose-dependent insulinotropic polypeptide fragment. Glucose-dependent insulinotropic polypeptide (GIP) is an incretin hormone that stimulates insulin secretion and reduces postprandial glycaemic excursions.

Highly potent GIP receptor agonist (EC50 = 630 ± 119 pM). Displays equivalent cAMP stimulating properties and improved resistance to enzymatic degradation compared to native GIP in cells expressing wild type GIP receptor. Improves glucose tolerance, insul

GIP receptor antagonist (IC50 = 2.6μM). Inhibits GIP-stimulated insulin release from pancreatic β cells in vitro. In ob/ob mice, blocks the effects of GIP on insulin release and plasma glucose levels. Also improves intraperitoneal glucose tolerance, insul

[Pro3]-GIP (Mouse) acetate is mouse [Pro3]-GIP. [Pro3]-GIP is a GIP receptor antagonist.

High affinity rat GIP receptor partial agonist (Kd = 13 nM). Increases cAMP accumulation in COS-7 cells transfected with rat GIP receptor, while also acting as a competitive antagonist of GIP.

GIP (1-39) acetate is a gastric inhibitory peptide (GIP) purified from porcine intestine and stimulates insulin secretion.

Potent insulinotropic hormone synthesized by duodenal K-cells. High affinity GIP receptor agonist (EC50 = 0.81 nM) that inhibits gastric acid secretion and stimulates pancreatic insulin release in response to glucose. Also affects lipid metabolism and dis

This GIP fragment has potent insulinotropic activity in the isolated, perfused rat pancreas but greatly reduced somatostatinotropic activity in the isolated perfused rat stomach. The site responsible for insulinotropic activity apparently lies between residues 19 and 30 of GIP.

(Pro3) GIP, human acetate (299898-52-5 Free base) is a potent, stable, and specific full agonist peptide for the human GIP receptor (GIPR). (Pro3) GIP, human acetate (299898-52-5 Free base) is the acetate salt form of a modified analog of natural GIP in which three alanine (Ala) residues have been mutated to proline (Pro). (Pro3) GIP, human acetate (299898-52-5 Free base) is a glucose-dependent insulin secretion (GIP) agonist and a weak inhibitor of gastric acid secretion.

NV03 is a selective antagonist of the UHRF1-H3K9me3 interaction (Kd=2.4 μM), binding to the UHRF1 tandem Tudor domain (TTD) to form a complex. It is suitable for cancer research. NV03 also functions as a ligand for E3 ligases in PROTAC synthesis.

Acetyl Gastric Inhibitory Peptide (human) TFA, a fatty acid-derivatized analog of the glucose-dependent insulinotropic polypeptide, exhibits enhanced antihyperglycemic and insulinotropic properties. It is utilized in the research of diabetes, insulin resistance, and obesity [1] [2] [3].

Gastric Inhibitory Peptide (1-42) (porcine) TFA is a glucose-dependent insulinotropic polypeptide released by intestinal K-cells. It stimulates insulin secretion while inhibiting gastric acid secretion and gastrointestinal motility, thereby regulating digestive function.

Gastric inhibitory peptide 1 (GIP-1) (3-42), a fragment of the incretin hormone GIP and antagonist to the GIP receptor, is generated through the action of serum dipeptidyl peptidase 4 (DDP-4). When administered at 25 nmol/kg to an ob/ob mouse diabetes model, GIP-1 (3-42) elevates plasma glucose levels and lowers plasma insulin levels, demonstrating its effect on reducing insulin secretion from BRIN-BD11 pancreatic cells at a concentration of 100 nM.

Gastric inhibitory peptide (GIP) (22-51), a pro-atherogenic peptide comprised of 30 amino acids from the residues 22-51 of its precursor protein proGIP, is present in human plasma. It activates the degradation of IκB-α and the nuclear translocation of NF-κB in both macrophage-differentiated THP-1 cells and human aortic endothelial cells at a concentration of 1 µM. Additionally, in ApoE-/- mice, GIP (22-51) escalates the area of atherosclerotic lesions and plaque development in vivo.

Neochlorogenic acid methyl ester (5-O-Caffeoylquinic acid methyl ester), derived from Artemisia capillaris and black chokeberry [Aronia melanocarpa] fruits, exhibits weak anti-HBV activity, antioxidant properties, and quinone reductase activity with a CD of 6.7 μM.

IUB0271 (acyl-GIP) is a long-acting acylated glucose-dependent insulinotropic polypeptide (GIP). It enhances cFos neuronal activity in the hypothalamic feeding centers of DIO mouse models and reduces body weight, food intake, and blood glucose levels, effects dependent on CNS-GIPR signaling. IUB0271 is applicable in research on type 2 diabetes (T2DM) and obesity.

IUB0271 (acyl-GIP) hydrochloride is a long-acting acylated glucose-dependent insulinotropic polypeptide (GIP). This compound enhances cFos neuron activity in the hypothalamic feeding centers of DIO mouse models, resulting in reduced body weight, food intake, and blood glucose levels, effects that rely on CNS-GIPR signaling. IUB0271 hydrochloride is applicable in research on type 2 diabetes (T2DM) and obesity.